Vol. 6 No. 7 (2026): July
Reimbursement Recommendations

Tafasitamab (Minjuvi)

decorative image of the issue cover

Published July 20, 2026

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Minjuvi be reimbursed by public drug plans “in combination with rituximab and lenalidomide [rituximab-lenalidomide] for the treatment of adult patients with grade 1, 2, or 3a relapsed or refractory follicular lymphoma [FL]” if certain conditions are met.
  • Evidence from 1 clinical trial showed that Minjuvi in combination with rituximab-lenalidomide improved progression-free survival (PFS) compared with rituximab-lenalidomide alone in patients with grade 1, 2, or 3a relapsed or refractory FL. The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) determined that adding Minjuvi to rituximab-lenalidomide provides acceptable clinical value compared with rituximab-lenalidomide alone for the treatment of grade 1, 2, or 3a relapsed or refractory FL. This determination was enough for pERC to recommend that Minjuvi be reimbursed. Given that Minjuvi is expected to be an additive treatment to rituximab-lenalidomide, acceptable clinical value refers to added benefit over rituximab-lenalidomide alone. pERC also determined that Minjuvi in combination with rituximab-lenalidomide addresses the need identified by both patients and clinicians for additional chemotherapy-free treatment options that are feasible for administration in a community setting.
  • Minjuvi in combination with rituximab-lenalidomide should only be covered for adults with relapsed or refractory grade 1, 2, or 3a FL who have received at least 1 previous treatment with systemic anti-CD20 immunotherapy or chemoimmunotherapy for the condition. Patients should have good performance status and should not have a nonfollicular indolent lymphoma or active lymphoma in the brain.
  • Minjuvi should only be reimbursed if treatment is started in combination with rituximab-lenalidomide, the patient is under the care of a clinician who has expertise in managing FL and supports are available for managing infusion-related reactions, and the cost of Minjuvi is reduced. Treatment should be discontinued upon completion of 12 treatment cycles or if the patient experiences disease progression or unacceptable side effects.
  • Important budget impact considerations must be addressed for health systems to be able to adopt Minjuvi in combination with rituximab-lenalidomide.